Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Investing in stocks based on valuation metrics is considered a smart strategy. The price-to-earnings (P/E) ratio is often the go-to metric due to its simplicity and ease of use. However, the ...

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $27.94, representing a 19.05% upside. In a report released on May 19, BMO Capital also maintained a Buy rating on the ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

In addition to Cantor Fitzgerald, Pfizer also received a Hold from Citi’s Geoff Meacham in a report issued on May 14. However, yesterday, BMO Capital maintained a Buy rating on Pfizer (NYSE: PFE). PFE ...

These four quality stocks trading at or near their 52-week lows come with stellar dividends that could be massive bargains ...

There are instances where high-yielding stocks can simply be great deals. Three stocks that pay at least 6% and don't look ...

Pfizer’s stock surged up to 11 percent after the pharma giant reported a robust 85 percent year-on-year rise in net profit ...

Gujarat Gas Limited, Quess Corp, Power Finance Corporation, and Eris Lifesciences Limited will also report their quarterly ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investing.com -- Moody’s Ratings has assigned an A2 rating to Pfizer Netherlands International Finance B.V. (PNIF BV), a ...